News

As part of the deal, Immunocore will conduct a Phase Ib/II trial combining MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100 to treat patients with metastatic melanoma. MEDI4736 and/or

Both the firms will advance the development candidate through IND-enabling studies to prepare for the initiation of clinical trials. As part of the deal, BMS has the first

As part of the amended deal, certain existing milestones and funding obligations have been revised, and the deal has been expanded to include select pre-commercialization activities. In total,

TrojanTec is a discovery research and development company affiliated with UK’s Imperial College London. TR-1 is a potent and specific replacement therapy of wild type p53/p21, which represents

As part of the deal, Senju acquires the exclusive rights to develop and commercialize microdosed therapeutics in Japan and the rest of Asia. Apart from the licensing deal,

The drug is approved for use in certain people who have chronic heart failure caused by the lower-left part of their heart not contracting well. Corlanor is indicated

According to the company, this all-oral treatment is interferon (IFN) and ribavirin (RBV)-free and will be dosed once daily. In February 2015, the company submitted a new drug

Tremelimumab is one of a number of immuno-oncology products being developed by AstraZeneca and MedImmune to harness the body’s own immune system to fight cancer. The drug stimulates

In 2010, NewLink Genetics licensed Ebola vaccine candidate from its original developer the Public Health Agency of Canada’s National Microbiology Laboratory. Merck and NewLink have entered into an